Dr. Monath is a Partner, Pandemic and Biodefense Fund, Kleiner Perkins Caufield & Byers. He is also Adjunct Professor, Harvard School of Public Health. Between 1992 and 2006, Dr Monath was Chief Scientific Officer and an Executive Director, Acambis (a publicly traded biopharmaceutical company) where he directed R&D on dengue, West Nile, Japanese encephalitis, yellow fever, Clostridium difficile , and smallpox vaccines for defense against bioterrorism. kpcb
The professional profile on LinkedIn for Dr Thomas P Monath MD. LinkedIn is a networking tool that helps users like Dr Thomas P Monath MD discover inside connections... www.linkedin.com/pub/2/69/231
The professional profile on LinkedIn for Dr Thomas P Monath MD. LinkedIn is a networking tool that helps users like Dr Thomas P Monath MD discover inside connections... www.linkedin.com/pub/3/4a4/6b
The professional profile on LinkedIn for Dr Thomas P Monath MD. LinkedIn is a networking tool that helps users like Dr Thomas P Monath MD discover inside connections... www.linkedin.com/pub/4/680/93a
... as well as possibly Dr. Thomas Monath, the Vice President of OraVax/Acambis and affiliated officials at Aventis. I've also urged an inquiry into ATCC curator Dr. Joshua Lederberg, and the... www.rumormillnews.com/cgi-bin/archive.cgi?read=15009
"It's really a good time to be in the vaccine business," says Dr. Thomas P. Monath, research chief at Acambis Inc. www.vaccinetruth.org/finacial_statement.htm